Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges
Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...
Q4 2024 Imunon Inc Earnings Call
Stacy Lindborg; Independent Director; Imunon Inc. Presentation. Operator. Good morning. My name is Mike, and I will be your operator today. At this time, I would lik ...
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...
Imunon reports 2024 EPS ($1.62) vs. ($2.16) last year
Ended 2024 with $5.9M in cash and cash equivalents. The company believes it has sufficient capital resources to fund its operations into late ...
Imunon, Inc.: IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...
Finanznachrichten8d
Imunon, Inc.: IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
These data also give us new levels of insight confirming the potential of our TheraPlas technology platform," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "We are ...
Morningstar8d
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...
The Pharma Letter7d
New Phase II data confirm promise of Imunon’s IMMN-001
New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...
manilatimes9d
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...